Advanced search
Publication Cover
Journal of Medical Economics Volume 13, 2010 - Issue 1
Submit an article Journal homepage
1,591
Views
18
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective

Nic Brereton University of Sheffield, Sheffield, UKCorrespondence[email protected]
,
Keith Bodger School of Clinical Sciences, University of Liverpool, Liverpool, UK
,
Michael A. Kamm St Vincent's Hospital and Melbourne University, Melbourne, AU, and Imperial College, London, UK
,
Paul Hodgkins Global Health Economics and Outcomes Research, Shire Pharmaceuticals, Wayne, PA, USA
,
Songkai Yan Global Health Economics and Outcomes Research, Shire Pharmaceuticals, Wayne, PA, USA
&
Ron Akehurst University of Sheffield, Sheffield, UK
Pages 148-161 | Published online: 08 Feb 2010

Citations (18)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (6)

Alexandre Gherardi, Stéphane Roze, Johan Kuijvenhoven, Ola Ghatnekar & Yum Lina Yip Sonderegger. (2018) Budesonide with multi-matrix technology as second-line treatment for ulcerative colitis: evaluation of long-term cost-effectiveness in the Netherlands. Journal of Medical Economics 21:9, pages 869-877.
Read now
Kabirraaj Toor, Eric Druyts, Jeroen P. Jansen & Kristian Thorlund. (2015) Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis. Journal of Medical Economics 18:6, pages 437-446.
Read now
Anthony O’Connor & Alan C Moss. (2014) Current and emerging maintenance therapies for ulcerative colitis. Expert Review of Gastroenterology & Hepatology 8:4, pages 359-368.
Read now
Susana Murteira, Zied Ghezaiel, Slim Karray & Michel Lamure. (2013) Drug reformulations and repositioning in pharmaceutical industry and its impact on market access: reassessment of nomenclature. Journal of Market Access & Health Policy 1:1.
Read now
Kavinderjit Nanda & Alan C Moss. (2012) Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine. Clinical Pharmacology: Advances and Applications 4, pages 41-50.
Read now
Sara N Horst & Sunanda Kane. (2012) Multi-Matrix System (MMX®) mesalamine for the treatment of mild-to-moderate ulcerative colitis. Expert Opinion on Pharmacotherapy 13:15, pages 2225-2232.
Read now

Articles from other publishers (12)

Mary Kaye Willian, Geert D’Haens, Aaron Yarlas & Ashish V. Joshi. (2018) Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label study. Journal of Patient-Reported Outcomes 2:1.
Crossref
Lachaine Jean, Miron Audrey, Catherine Beauchemin & on behalf of the iGenoMed Consortium. (2018) Economic Evaluations of Treatments for Inflammatory Bowel Diseases: A Literature Review. Canadian Journal of Gastroenterology and Hepatology 2018, pages 1-14.
Crossref
Nadia Pillai, Mark Dusheiko, Bernard Burnand & Valérie Pittet. (2017) A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease. PLOS ONE 12:10, pages e0185500.
Crossref
Rachel Archer, Paul Tappenden, Shijie Ren, Marrissa Martyn-St James, Rebecca Harvey, Hasan Basarir, John Stevens, Christopher Carroll, Anna Cantrell, Alan Lobo & Sami Hoque. (2016) Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. Health Technology Assessment 20:39, pages 1-326.
Crossref
Javier P. Gisbert, Fernando Gomollón & Ignacio Méndez. (2016) Evaluación de coste-efectividad mediante análisis teórico de minimización de costes del uso de dos mesalazinas gastrorresistentes de liberación prolongada en el manejo de la colitis ulcerosa en España. Gastroenterología y Hepatología 39:3, pages 199-212.
Crossref
Javier P. Gisbert, Fernando Gomollón & Ignacio Méndez. (2016) Cost-effectiveness assessment through theoretical cost-minimization analysis of the use of two gastro-resistant modified-release mesalazine formulations in the management of ulcerative colitis in Spain. Gastroenterología y Hepatología (English Edition) 39:3, pages 199-212.
Crossref
Brígida Mónica Faria, Joaquim Gonçalves, Luis Paulo Reis & Álvaro Rocha. (2015) A Clinical Support System Based on Quality of Life Estimation. Journal of Medical Systems 39:10.
Crossref
Bei Ye. (2015) Mesalazine preparations for the treatment of ulcerative colitis: Are all created equal?. World Journal of Gastrointestinal Pharmacology and Therapeutics 6:4, pages 137.
Crossref
Prabhjot Singh Sidhu, Ravi Karwa, Victoria Kenneth, Debi Oxley & Anurag Agrawal. (2014) Which 5-ASA? Understanding the choices in ulcerative colitis therapy. Gastrointestinal Nursing 12:5, pages 17-26.
Crossref
Anne Prenzler, Linnette Yen, Thomas Mittendorf & J-Matthias von der Schulenburg. (2011) Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine. BMC Health Services Research 11:1.
Crossref
Keith Bodger. (2011) Cost Effectiveness of Treatments for Inflammatory Bowel Disease. PharmacoEconomics 29:5, pages 387-401.
Crossref
Lily P.H. Yang & Paul L. McCormack. (2011) MMX® Mesalazine. Drugs 71:2, pages 221-235.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.